Injectable Oxygen Therapeutics for Perioperative Organ Protection

Abstract

Perioperative organ dysfunction remains a significant cause of morbidity and mortality among surgical patients, despite advances in anesthetic and surgical techniques. Hypoxia and ischemia-reperfusion injury are pivotal contributors, especially in high-risk surgeries. Injectable oxygen therapeutics, including hemoglobin-based oxygen carriers (HBOCs), perfluorocarbon emulsions, and other novel compounds, have emerged as promising adjuncts to enhance tissue oxygenation during perioperative periods. This review synthesizes current evidence, elucidates mechanisms of action, and examines clinical implications, recent advances, and guideline recommendations related to the use of injectable oxygen therapeutics for perioperative organ protection.

Introduction

Organ protection during the perioperative period is a critical concern in modern medicine, particularly for patients undergoing major surgeries with significant risk of hypoxia or ischemia-reperfusion injury. Despite substantial progress in surgical techniques and perioperative care, postoperative organ dysfunction, including acute kidney injury, myocardial infarction, and cerebral ischemia, continues to adversely affect outcomes. Traditional strategies, such as optimizing hemodynamics, ensuring adequate ventilation, and using blood transfusions, have limitations, motivating exploration of alternative means to improve perioperative oxygen delivery. Injectable oxygen therapeutics represent a novel intervention aimed at bridging oxygen delivery gaps, thus potentially reducing organ injury and improving patient outcomes.

Epidemiology / Disease Burden

Perioperative organ dysfunction affects an estimated 5-15% of patients undergoing major surgery, with higher incidence rates in cardiac, vascular, and transplant surgeries. Acute kidney injury alone occurs in up to 30% of high-risk surgical populations, often resulting in increased length of stay, higher healthcare costs, and reduced long-term survival. Global data suggest that perioperative hypoxia contributes significantly to morbidity, despite widespread use of supplemental oxygen and advanced monitoring. The burden is especially pronounced in elderly and comorbid populations, where even transient hypoxic episodes can precipitate multi-organ failure. Reducing the incidence and severity of perioperative organ injury remains a pressing clinical imperative.

Pathophysiology

Ischemia-reperfusion injury and sustained hypoxia are central to perioperative organ damage. During periods of low perfusion, tissues become deprived of oxygen, impairing cellular metabolism and promoting accumulation of anaerobic metabolites. Upon reperfusion, a surge of reactive oxygen species and inflammatory mediators exacerbates tissue injury. Endothelial dysfunction, microvascular thrombosis, and mitochondrial impairment contribute to organ dysfunction. Standard oxygen carriers, such as hemoglobin in red blood cells, can be inadequate under conditions of compromised perfusion or anemia. Injectable oxygen therapeutics are designed to enhance oxygen solubility and delivery at the microvascular level, bypassing some of the limitations of traditional therapies.

Risk Factors

Numerous factors increase the risk of perioperative organ injury, including advanced age, pre-existing cardiovascular or renal disease, diabetes, anemia, sepsis, prolonged surgical times, significant blood loss, and poor baseline functional status. Surgical procedures involving aortic cross-clamping, cardiopulmonary bypass, or organ transplantation are particularly high risk. Additionally, intraoperative hypotension, hypovolemia, and inadequate tissue perfusion predispose patients to hypoxic injury. Identifying at-risk individuals is essential for the targeted application of adjunctive therapies such as injectable oxygen carriers.

Clinical Features

Perioperative organ dysfunction may manifest as oliguria or anuria signaling acute kidney injury, altered mental status indicating cerebral hypoxia, arrhythmias or myocardial dysfunction reflecting cardiac ischemia, and lactic acidosis as a marker of global tissue hypoperfusion. These features often develop within hours to days postoperatively and are associated with poor outcomes if not promptly recognized and managed. Subclinical organ injury, detectable only through biomarkers or imaging, may also have long-term consequences.

Diagnosis

Diagnosis of perioperative organ injury relies on clinical assessment, laboratory studies (e.g., creatinine, troponin, lactate), imaging modalities (e.g., echocardiography, renal ultrasound), and functional monitoring (e.g., urine output, oxygen saturation). Early detection is crucial for timely intervention. Advanced techniques such as tissue oxygen tension monitoring and near-infrared spectroscopy are increasingly used to guide therapy in high-risk surgical settings. Biomarker-guided approaches may further enhance early identification of patients who could benefit from injectable oxygen therapeutics.

Treatment & Management

Current perioperative management strategies focus on optimizing oxygen delivery via intravenous fluids, vasopressors, supplemental oxygen, and blood transfusions when indicated. However, transfusion carries risks including immunologic reactions and infection, and may not always achieve adequate tissue oxygenation. Injectable oxygen therapeutics provide an alternative by directly increasing plasma oxygen content. HBOCs and perfluorocarbon emulsions can transport and release oxygen in hypoxic tissues more efficiently, supporting cellular metabolism during critical periods. Their use should be integrated with standard supportive measures tailored to the patient’s risk profile and surgical context.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the development of safer and more effective injectable oxygen therapeutics. Second-generation HBOCs, with improved molecular stability and reduced vasoactivity, have demonstrated benefit in preclinical and early clinical studies. Perfluorocarbon emulsions, capable of dissolving large volumes of oxygen, are under investigation for use in cardiac surgery, trauma, and transplantation. Novel agents such as artificial red blood cells and oxygen microbubbles are being evaluated in animal models for rapid oxygen delivery with minimal side effects. Advances in nanotechnology and molecular engineering promise further enhancements in oxygen-carrying capacity and biocompatibility, potentially expanding the clinical indications for these agents.

Guideline Recommendations

Current perioperative guidelines acknowledge the experimental status of injectable oxygen therapeutics, recommending their use primarily within clinical trial settings or as rescue therapy when conventional measures fail. The American Society of Anesthesiologists and European Society of Anaesthesiology highlight the need for further large-scale, randomized trials to establish safety, efficacy, and optimal patient selection. Until more robust data are available, these agents should be considered investigational, with careful risk-benefit assessment and close monitoring for adverse effects such as vasoconstriction, oxidative stress, or immunogenic reactions.

Conclusion

Injectable oxygen therapeutics represent a promising adjunct for perioperative organ protection, particularly in high-risk surgical populations vulnerable to hypoxic injury. Mechanism-based innovations have led to the development of safer and more effective carriers, with early evidence supporting their role in enhancing tissue oxygenation when conventional therapies are insufficient. While current guidelines advise caution and recommend use within research protocols, ongoing clinical trials are likely to clarify the therapeutic potential and inform future practice. Multidisciplinary collaboration and continued research are essential to realize the full benefits of these emerging therapies in improving perioperative outcomes and patient safety.